

Akebia Therapeutics to Host Fourth Quarter and Full-Year 2018 Investor Update Call and Webcast

March 6, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 6, 2019-- Akebia Therapeutics, Inc. (Nasdaq:AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced it will host a fourth quarter and full-year 2018 investor update conference call and webcast at 4:30 p.m. Eastern Time on Monday, March 18, 2019.

Individuals interested in participating in the call should dial (877) 458-0977 (U.S. and Canada) or (484) 653-6724 (international) using conference ID number 1376157. To access the webcast, visit the Investors section of Akebia's website at www.akebia.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

Beginning the morning of March 19, 2019, the call will be available for replay via telephone and the archived webcast will be available on Akebia's website. To listen to the telephone replay, dial (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international) using conference ID number 1376157. The telephone replay will be available for six days following the call.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com which does not form a part of this release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190306005227/en/

Source: Akebia Therapeutics, Inc.

Akebia Therapeutics Contact Argot Partners Melissa Forst / Maghan Meyers (212) 600-1902